Vetter Advances New U.S. Site and Upgrades Austrian Facility
In response to the growing demand for in-human trial material, German CDMO Vetter is expanding its clinical manufacturing network with new infrastructure in the U.S. and Austria.
Vetter Pharma has announced significant progress in the ongoing expansion of its clinical manufacturing sites in the U.S. and Europe. The site upgrades, outlined in a corporate press release (1), focus on the company’s existing clinical facilities in Skokie, Illinois and Rankweil, Austria, as well as on the new purpose‑built clinical site under construction in Des Plaines, Illinois, for short‑run, high‑complexity drug product development.
In the U.S., Vetter is advancing construction of its new aseptic clinical manufacturing site in Des Plaines, Illinois, following the groundbreaking ceremony held on June 26, 2025 (2). The interior construction of the 160,000‑square‑foot facility is set to begin shortly, with the project still on track for completion and readiness for media fill by the end of 2029. Additionally, the company’s site at Skokie, Illinois, will continue to serve as a key hub for global biotech partners tackling the challenges of clinical development, and has supported more than 140 customers and over 350 compounds since it opened.
Within European, Vetter’s Rankweil clinical site in Austria is being upgraded with several infrastructure enhancements to handle higher project volumes and more complex drug product development workflows. The enhancements include a new weighing room, an additional compounding room within the aseptic production area, and expanded manual visual inspection capacity, alongside added cold‑storage rooms, specialized API freezers, and an extra incubator chamber to strengthen microbiological testing (1).
“Our continued global expansion reflects our holistic approach to supporting our customers throughout their clinical development,” said Dr. Claus Feussner, Senior Vice President of Vetter Development Service, in a company press release (1). “By investing in both technology and capacity, we are working to provide our partners with tailored early‑stage manufacturing services that enable their molecules to progress successfully from the lab to the clinic.”
Vetter Pharma’s expansion of its U.S. and European clinical manufacturing sites reflects a wider industry‑wide shift toward greater capacity, flexibility, and regionalization in clinical‑stage drug manufacturing. Vetter’s continued investments in facilities and infrastructure will match the evolving needs of biotech and pharma partners navigating an increasingly competitive and regulated clinical manufacturing landscape.
References
Vetter Pharma. We Strengthen Our Global Clinical Manufacturing Network with Strategic Site Enhancements. News, April 14, 2026.
Thomas, F. Vetter Breaks Ground on New U.S. Clinical Manufacturing Site. The Pharma Navigator, News, July 3, 2025.